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ABSTRACT
Cervical cancer is one of the leading causes of death among women suffering 
from tumors. Current treatment options are insufficient. Here, we investigated the MET 
receptor as a potential molecular target in advanced cervical cancer. Downregulation 
of MET receptor expression via RNA interference in different cervical carcinoma cell 
lines dramatically decreased tumor growth and forced tumor differentiation in vivo. 
MET receptor silencing also led to a dramatic decrease in cell size and a decrease in 
proliferation rate under normal and stress conditions. MET receptor downregulation 
also resulted in decreased cyclin D1 and c-myc levels but did not increase apoptosis. 
Subsequent experiments showed that downregulation of the MET receptor decreased 
the expression of a key regulator of the epithelial-to-mesenchymal transition, SLUG. 
and increased the expression of E-cadherin, a hallmark of the epithelial phenotype. 
Moreover, MET downregulation impairs expression and signaling of CXCR4 receptor, 
responsible for invasive phenotype.
Taken together, our results strongly suggest that the MET receptor influences the 
oncogenic properties of cervical carcinoma cells in vitro and in vivo. These findings 
highlight a unique role of the MET receptor in cervical carcinoma cells and indicate 
the MET receptor as a potential therapeutic target for advanced cervical carcinoma.
INTRODUCTION
Despite the recent development of a vaccine against 
human papillomavirus infection, cervical cancer (CC) 
remains the third leading cause of death among women 
suffering from cancer, especially in low- and middle-
income countries [1, 2]. The survival rate for CC is related 
to the stage of the disease with distant metastasis. There is 
currently no effective therapy for advanced cervical cancer, 
and it is thus important to identify molecular markers that 
can help in the development of new therapeutic strategies 
to improve cervical cancer treatment.
The MET receptor belongs to the family of growth 
factor receptors with intrinsic tyrosine kinase activity and, 
together with its ligand, Hepatocyte Growth Factor (HGF), 
is involved in proliferation, inhibition of apoptosis, 
motility and dissemination of cancer cells during tumor 
development and progression [3, 4]. HGF and the 
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MET receptor are also known to mediate epithelial-
to-mesenchymal transitions (EMT) during embryonic 
development [5, 6] and tumorigenesis [7, 8].
EMT is a stage of metastasis in which epithelial cells 
acquire characteristics of mesenchymal stem cells [9]. EMT 
is regulated by a number of transcription factors, including 
SNAIL1, SLUG, ZEB1, ZEB2, and TWIST [10, 11] and 
is characterized by E-cadherin suppression, increased 
levels of N-cadherin and vimentin expression, and a highly 
invasive mesenchymal phenotype [12, 13, 14]. The MET 
receptor is overexpressed in a variety of human cancers, 
including thyroid carcinoma [15], ovarian cancer [16], 
colorectal cancer [17], rhabdomyosarcoma [18], and renal 
cell carcinoma [19]. It has been also shown that hepatocyte 
growth factor (HGF) and its receptor MET are significantly 
increased in ovarian cancer patients who relapse shortly 
after chemotherapy [20]. In cervical carcinoma, the 
MET receptor has been shown to promote scattering and 
morphogenesis of tumor cells [20, 21]. We previously 
showed that stimulation of the MET receptor with HGF 
alone or together with stromal-derived factor-1 (SDF-1), 
the ligand for the CXCR4 receptor, results in migration and 
cytoskeletal changes in cervical carcinoma cells [22]. Our 
data also showed that activation of both MET and CXCR4 
caused the translocation of β-catenin into the nucleus and 
the subsequent upregulation of cyclin D1 expression [22].
In the present study, we used cell lines as well as 
tumor tissues to evaluate the role of the MET receptor 
in cervical cancer. We investigated whether the MET 
receptor is involved in the growth and progression 
of human cervical carcinoma in vitro and in vivo and 
whether silencing of this gene can change the cellular 
phenotype into a more benign form and thereby arrest 
cancer development. We demonstrate, for the first time, 
that downregulation of the MET receptor can reverse the 
EMT-driven cervical cancer cell phenotype into a more 
epithelial and less aggressive form. We further show 
that the MET receptor might be a promising target for 
advanced cervical cancer therapy.
RESULTS
MET receptor expression in patients’ samples
Immunohistochemical analysis of 31 patients’ tissues 
revealed that MET receptor expression varies depending 
on the grade of the tumor (Figure 1). Examples of 
immunohistochemical staining of LSIL, HSIL and invasive 
carcinoma are presented in Figure 1A. In order to perform 
staining analysis of MET receptor we used the scale from 
0 to 4, where 0 (+/−) – very poor response/poorly positive 
discontinuous, 1 (+) – poor response, 2 (++) – moderate 
response, 3 (+++) – quite strong/strong response, 4 (++++) – 
very strong response. The immunohistochemical analysis 
revealed strong positive staining for MET receptor in over 
80% of HSIL samples and strong and very strong positive 
reaction for 67% of invasive carcinoma (Figure 1B). 
Histopathological examination also showed that LSIL 
was characterized mainly by a poor expression of MET 
receptor (+). Strong (+++) and very strong (++++) MET 
expression we observed for samples described as HSIL 
and invasive carcinoma (Figure 1C).
MET downregulation reduces the viability/
proliferation of MET-deficient cells under stress 
conditions
Cervical carcinoma cells were transduced with 
lentiviral vectors containing anti-MET shRNAs that 
were established in our laboratory [23]. The efficiency 
of MET downregulation was assessed in cells transduced 
with control LacZ (shLacZ) and MET (shMET) shRNA 
and compared with control wild-type (WT) cells. MET 
receptor expression levels were evaluated at the mRNA 
level using real-time RT–PCR (Figure 2A) and at the 
protein level using flow cytometry (Figure 2B) and 
western blot analysis (Figure 2C). The functionality of 
the silenced receptor was tested by a chemotaxis assay 
(Supplementary Figure 1).
The growth of tumors in vivo induces specific 
conditions associated with limited access to oxygen and 
nutrients. The MET receptor promotes cell viability and 
proliferation during tumorigenesis [4]. To test whether 
the MET receptor influences cell viability/proliferation 
under stress conditions, cells were cultured in starvation 
medium (0.5% BSA) or under low oxygen (2%), and the 
MTT assay was performed. For the HTB-34 and HeLa cell 
lines, we did not observe any differences between control 
cells and MET-deficient cells under either starvation or low 
oxygen conditions (Figure 2D, 2E, left and middle panels). 
However, MET receptor downregulation significantly 
decreased the viability/proliferation of HTB-35 cells after 
48 hours of starvation or hypoxic conditions. The largest 
difference between control and MET-deficient cells was 
reached after 96 hours of culture (Figure 2D, 2E, right 
panels). These data showed that MET receptor expression is 
important for viability/proliferation of HTB-35 cells under 
stress conditions. It has been already shown that some 
tumors are dependent on MET receptor activity for their 
growth and survival [24, 25]. In subsequent experiments we 
wanted to know whether MET receptor might be relevant 
for other characteristics of cervical cancer cells.
MET receptor downregulation inhibits tumor 
growth in vivo
The reduced viability observed in the HTB-35 
shMET cell line led us to study the influence of MET 
receptor silencing on cell behavior during tumor formation 
in vivo. To examine the growth of human cervical cell lines 
in vivo, we established a xenotransplant model in NOD-
SCID mice. Mice were injected subcutaneously with 
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5 × 106 WT, shLacZ or shMET cells. After 30 days, the 
mice were sacrificed, and the tumors were weighed. We 
observed that HTB-34 cells formed tumors with an average 
weight of 0.3 grams (Figure 3A, left panel), whereas tumors 
formed by HeLa cells weighed on average 1.3 grams 
(Figure 3A, middle panel). Despite this discrepancy in 
tumor weight, the growth of HTB-34 and HeLa tumors 
was not inhibited by MET receptor downregulation 
(Figure 3A, left and middle panels). Tumors generated 
by WT and shLacZ HTB-35 control cells did not differ 
in weight, forming tumors of approximately 1.7 grams 
(Figure 3A, right panel). Interestingly, shMET HTB-35 
Figure 1: Immunohistochemical analysis of MET receptor expression in patient samples. (A) Examples of 
immunohistochemical staining of MET receptor for LSIL, HSIL and invasive carcinoma. (B and C) Immunohistochemical analysis of MET 
receptor expression in human samples. In order to perform expression analysis we used the following scale: 0 (+/−) – very poor response/
poorly positive discontinuous, 1 (+) – poor response, 2 (++) – moderate response, 3 (+++) – quite strong/strong response, 4 (++++) – 
very strong response. Samples were obtained from patients with mild, moderate or severe dysplasia and invasive cervical carcinoma. 
LSIL – Low-grade squamous Intraepithelial Lesion, HSIL – High-grade squamous Intraepithelial Lesion (according to Bethesda system 
terminology). The evaluation of the samples was performed with the approval from the Bioethics Committee of the Jagiellonian University 
(no. KBET/7/B/2008). n = 31, **p < 0.001. Bar = 200 μm.
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Figure 2: MET downregulation alters proliferation/viability under stress conditions. MET receptor downregulation via 
a lentiviral vector containing anti-MET shRNA resulted in decreases at mRNA (A) and protein (B, C) levels. Downregulation of MET 
receptor alters proliferation/viability under hypoxia (D) and starvation (E) conditions. A – Real-time RT-PCR revealed significant decreases 
in MET transcript levels in MET receptor-silenced cells (shMET) relative to controls (wild type, WT, and shLacZ) in all tested cell lines 
(HTB-34, HeLa and HTB-35). B – Flow cytometry analysis of MET receptor expression. C – Western blot analysis revealed complete 
downregulation of MET receptor expression in shMET HTB-34, HeLa and HTB-35 cells. D. MTT assay of cells cultured under starvation 
conditions (MEM supplemented with 0.5% BSA). E – MTT assay of cells cultured under hypoxic conditions (2% oxygen). Western blot 
and FACS analyses were performed at least three times with similar results; representative results are shown. Real-time RT-PCR was 
performed at least three times in duplicates. MTT assay was repeated three times in triplicates. *p < 0.01, **p < 0.001.
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cells formed very small tumors, with a mean weight of 
only 0.08 grams (Figure 3A, right panel). Interestingly, 6 
of 15 animals injected with HTB-35 shMET cells did not 
develop tumors at all.
A histopathological analysis of the tumor lesions 
revealed no differences between the tumors generated 
by control and MET-deficient HTB-34 and HeLa cells 
(Figure 3B, first and second panels). However, tumors 
formed by shMET HTB-35 cells clearly differed from 
their control counterparts. Here, our histopathological 
examination revealed that MET-deficient cells formed 
well-differentiated tumors with keratin pearls, i.e., whorl-
shaped accumulations of keratin [26], whereas control 
tumors were poorly differentiated and composed of cells 
of various sizes and shapes with a large number of mitotic 
figures (Figure 3B, last panel). E-cadherin, a marker of 
the epithelial phenotype, was highly expressed in tumors 
generated by both control and shMET HTB-34 cells 
(Figure 3B, first panel). By contrast, both control and MET-
deficient HeLa cells formed tumors that did not express 
E-cadherin (Figure 3B, second panel). Interestingly, MET 
receptor downregulation in HTB-35 cells led to the re-
expression of E-cadherin in vivo (Figure 3B, last panel).
Downregulation of the MET receptor inhibits 
cell proliferation by decreasing cyclin D1 and 
c-myc levels
The inhibition of tumor growth observed in our in 
vivo studies directed our interest towards the properties 
of HTB-35 shMET cells. We first studied the growth of 
shMET cells. The cells were incubated under control 
conditions (10% FBS) and counted every 24 hours. We 
observed growth inhibition of shMET HTB-35 cells 
relative to WT and LacZ cells (Figure 4A). The difference 
in growth rate between control and shMET cells was 
Figure 3: Tumor growth in vivo and histopathological analysis of control and shMET cervical carcinoma cells.  
A comparison of tumors derived from control and shMET cervical carcinoma cells revealed differences in tumor weight, morphology and 
E-cadherin expression. (A) Tumor growth of WT, shLacZ and shMET cervical carcinoma cells was measured 30 days after subcutaneous 
injection of 5 × 106 cells in NOD-SCID mice. (B) H&E staining showing that MET silencing did not influence the morphology of HTB-34 
and HeLa tumors, whereas HTB-35 shMET tumors resembled more differentiated tumors with keratin pearls (arrows). E-cadherin is highly 
expressed in HTB-34 cells but absent in HeLa cells. Downregulation of MET in HTB-35 cells caused the re-expression of E-cadherin. 
These experiments were performed three times with n = 5; **p < 0.001. Representative staining is shown. Bar = 50 μm.
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significant at each time point tested. The proliferation rate 
of control cells was four times higher than that of shMET 
HTB-35 cells after 96 hours of culture.
To explore the reason for the decreased proliferation 
of MET-deficient cells, we analyzed apoptosis patterns 
and cell cycle progression. HTB-35 shMET cells did not 
undergo apoptosis spontaneously, and we did not observe 
any differences between control and shMET cells in 
early (AnnexinV+PI–) or late apoptosis (AnnexinV+PI+) 
(Figure 4B). However, there was a difference in cell cycle 
progression, as MET receptor downregulation decreased 
the number of cells in S phase and increased the number 
of cells in G2/M phase (Figure 4C). Cyclin D is known 
to regulate the entry into S-phase [27], and c-myc, as 
a transcriptional regulator, mediates processes such as 
proliferation, differentiation, transformation and prevention 
of apoptosis [28, 29]. Transcript levels of both genes were 
significantly downregulated after MET downregulation, 
with eight- and five-fold reductions observed for cyclin D1 
and c-myc, respectively (Figure 4D). To confirm this result, 
we measured their protein levels in shMET cells by western 
blotting and detected only a faint signal for c-myc and no 
signal for cyclin D1 (Figure 4E). We also observed the 
influence of the MET receptor depletion on the expression 
level of genes correlated with invasive phenotype, 
angiogenesis and tumor growth. Downregulation of MET 
receptor decreases mRNA level of c-myc, CXCR4 and Slug 
and increases mRNA of HGF, CXCR7, HIF-1α, matrix 
metalloproteinases −2, −9 (MMP-2, −9) and tissue inhibitor 
of metalloproteinases −1, −2 (TIMP-1,−2). (Supplementary 
Table 1).
MET downregulation alters cell morphology
MET receptor downregulation significantly affected 
the morphology of HTB-35 cells. After transduction with 
the shMET lentiviral vector, the cells became small and 
rounded, whereas control cells resembled fibroblast-like 
cells with an elongated shape (Figure 5A). The values 
for all cell morphology parameters (area, periphery, 
extension, dispersion and elongation) were significantly 
lower in HTB-35 shMET relative to control cells. The 
data are summarized in Table 1. We also observed that 
MET downregulation altered F-actin organization. In 
Figure 4: Influence of the MET receptor on cell function. (A) Proliferation assay in HTB-35 cells. A significant decrease in 
proliferation rate was observed after MET silencing. Cells were cultured in medium supplemented with 10% FBS and counted every 24 
hours. (B) Flow cytometry analysis of Annexin V and PI staining of control and MET-deficient HTB-35 cells did not reveal any differences. 
(C) Cell cycle analysis revealed that MET receptor downregulation decreased the proportion of cells in S phase and caused an accumulation 
in G2/M phase. (D) Real-time RT-PCR analysis of cyclin D1 and c-myc expression. Significant downregulation of cyclin D1 and c-myc 
was observed at the mRNA level after MET receptor downregulation. (E) Western blot analysis of c-myc and cyclin D1 protein expression. 
c-myc was weakly expressed in shMET HTB-35 cells, whereas cyclin D1 decreased to an undetectable level. Proliferation assay was 
performed three times in triplicate and real-time RT-PCR assays was performed three times in duplicate. FACS and western blot analyses 
were performed at least three times with similar results. Representative results are shown. **p < 0.001. ##. p < 0.005.
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MET-deficient HTB-35 cells, F-actin was located under 
the cell membrane and did not form regular stress fibers 
as observed in WT and shLacZ cells. Actin filaments 
reorganized from thick, parallel, contractile bundles in 
control cells to thin cortical bundles – as in epithelial cells 
– in MET-deficient cells (Figure 5B).
E-cadherin and slug expression in patients’ samples
Immunohistochemical study of 37 patients’ samp-
les showed low E-cadherin expression in high-grade 
intraepithelial lesion (HSIL) and invasive carcinoma 
Figure 6A. To our surprise, a significant decrease in the 
E-cadherin was also observed for low-grade squamous 
intraepithelial lesion (LSIL) in comparison to normal 
cervix (Figure 6A, Supplementary Table 2). Slug 
expression was higher in HSIL and invasive carcinoma in 
comparison to LSIL (Figure 6B; Supplementary Table 3).
MET receptor downregulation influences 
E-cadherin and slug expression
Because MET receptor downregulation in HTB-
35 shMET cells led to a lower proliferation rate along 
with an altered cell shape and F-actin reorganization, we 
assumed that MET silencing at least partially reversed 
their phenotype into a less aggressive form. To expand 
on these observations, we evaluated potential changes in 
the expression of various EMT markers. MET receptor 
silencing upregulated E-cadherin and suppressed Slug and 
Vimentin mRNA expression in HTB-35 cells (Figure 7A). 
An immunofluorescence analysis of E-cadherin distribution 
Figure 5: Cell morphology and actin organization after MET silencing. An analysis of cell morphology revealed a decrease 
in cell size (A) and changes in F-actin organization (B) in MET-deficient HTB-35 cells. A – Cells were photographed with Nomarski 
interference contrast (upper panel) and analyzed with MIGRA software (lower panel). B – Immunofluorescence staining of the F-actin 
cytoskeleton shows re-organization of actin filaments from thick contractile bundles in control cells to thin cortical bundles – as in epithelial 
cells – in MET-deficient cells. Representative staining is shown. Bar = 50 μm., ## p < 0.005.
Table 1: The values for cell morphology parameters - area, periphery, extension, dispersion and 
elongation
Cell line Area Periphery Extension1 Dispertion1 Elongation1
HTB-35 WT 885.85 ± 12.99 159.99 ± 5.87 1.05 ± 0.56 0.17 ± 0.32 0.88 ± 0.47
HTB-35 shLacZ 963.42 ± 423.58 178.63 ± 36.73 1.07 ± 0.51 0.16 ± 0.12 0.91 ± 0.46
HTB-35 shMET 343.94 ± 41.08## 90.62 ± 15.91## 0.24 ± 0.13## 0.03 ± 0.02## 0.22 ± 0.12##
1Extension,dispersion and elongation take a value 0 if the shape is circular and increases without limit as the shape becomes 
less compact [51]. The mean value was obtained from analysis of 50 cells. Statistically significant at ## p < 0.005.
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showed that in control cells, E-cadherin was present in 
discrete, disrupted dots, whereas MET-deficient cells 
showed lateral membrane localization at sites of cell-cell 
contact (Figure 7B). A western blot analysis revealed 
that Slug protein levels were very low and absent in the 
cytosolic fractions of control and shMET HTB-35 cells, 
respectively. In the nuclear fraction, Slug expression was 
very strong in control cells but undetectable in MET-
deficient cells (Figure 7C). Based on our in vivo observation 
that MET-deficient tumors were more differentiated than 
controls and re-expressed E-cadherin, we examined Slug 
expression in tumor specimens. This immunohistochemical 
analysis revealed that tumors formed by control HTB-35 
cells presented high Slug expression in nuclei and low 
expression (pale staining) in the cytoplasm. By contrast, 
tumors derived from shMET HTB-35 cells exhibited no 
Slug expression in nuclei and very low expression in the 
cytoplasm (Figure 7D).
Our histopathological analysis showed that 
E-cadherin was highly expressed in tumors generated by 
both control and shMET HTB-34 cells (Figure 3B) and 
we were interested whether MET receptor downregulation 
affects expression of some EMT markers (Supplementary 
Figure 2). HTB-34 WT, shLacZ and shMET cells 
had similar, high level of E-cadherin at mRNA level. 
MET deficient HTB-34 cells showed decreased 
SLUG expression and undetectable level of Vimentin 
(Supplementary Figure 2A). Moreover, we observed 
that control and shMET HTB-34 cells have very low 
expression of CXCR4 (Supplementary Figure 2B).
MET receptor downregulation impairs CXCR4 
expression and activation
SDF-1-CXCR4 axis is a key player responsible 
for invasive phenotype and metastatic behavior of many 
tumor types [30, 31]. In our study, we evaluated the level 
of CXCR4 expression in human samples (n = 31) obtained 
from cervical carcinoma patients. Regardless of the cancer 
stage, we observed strong and very strong expression of 
CXCR4 receptor (Figure 8A; Supplementary Table 4). 
We became interested whether downregulation of MET 
receptor influences SDF-1/CXCR4 axis. We noticed that 
the expression of CXCR4 was strongly decreased in shMET 
HTB-35 and unchanged in control HTB-35 cell lines 
(Figure 8B). After the activation of CXCR4 receptor with 
SDF-1 we found that control cells responded to the ligand 
by phosphorylation of AKT and MAPK kinases. However, 
the activation of MAPK and AKT after SDF-1 stimulation 
was highly impaired in shMET HTB-35 cells (Figure  8C). 
These data led us to the question how MET receptor 
influence the chemotactive activity of CXCR4 receptor. 
We found that downregulation of MET receptor drastically 
impaired directed migration towards HGF and SDF-1 
ligands (Figure 8D). HTB-34 control and shMET cells did 
not express CXCR4 receptor (Supplementary Figure 2).
Figure 6: Immunohistochemical analysis of E-cadherin (A) and Slug (B) expression in patient samples. Samples were obtained from 
patients with mild, moderate or severe dysplasia and invasive cervical carcinoma. LSIL – Low-grade squamous Intraepithelial Lesion, 
HSIL – High-grade squamous Intraepithelial Lesion (according to Bethesda system terminology). **p < 0.001; # p < 0.05.
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Figure 7: E-cadherin, SLUG and Vimentin expression after MET receptor downregulation. Control cells had undetectable 
levels of E-cadherin (a hallmark of the epithelial phenotype) as well as high expression of SLUG (a driver of EMT) and Vimentin. 
MET receptor downregulation increased E-cadherin and decreased SLUG and Vimentin expression. (A) Real-time RT-PCR analysis of 
E-cadherin, SLUG and Vimentin expression. (B) Immunofluorescence analysis of E-cadherin levels and localization. (C) An analysis of 
SLUG expression revealed reduced levels of SLUG mRNA and undetectable SLUG protein in both the cytosolic and nuclear fractions 
after MET downregulation. (D) Immunohistochemical staining for SLUG revealed high expression in control cells, with primarily nuclear 
localization. Tumors formed by MET-deficient cells did not express SLUG. These experiments were performed at least three times. 
Representative staining is shown. Bar = 50 μm. **p < 0.001.
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Figure 8: MET receptor downregulation decreases CXCR4 expression and function. (A) Immunohistochemical analysis of 
CXCR4 receptor expression in human tissue. (B) Real-time RT-PCR and flow cytometry analysis revealed significant decreases in MET 
transcript and protein levels in MET receptor-silenced cells (shMET) relative to controls (wild type, WT, and shLacZ). (C) Western blot 
analysis of CXCR4 activation. AKT and MAPK phosphorylation was tested after after HGF and SDF-1 stimulation. (D) In chemotaxis 
assay MET-deficient CC cells showed limited chemotactic activity towards HGF and/or SDF-1 gradient. Western blot and FACS analyses 
were performed three times with similar results; representative results are shown. Real-time RT-PCR and chemotaxis assays were performed 
at least three times in duplicate. *p < 0.01, **p < 0.001.
Oncotarget10096www.impactjournals.com/oncotarget
DISCUSSION
Cervical cancer is the third most common tumor 
in women. According to WHO statistics, the worldwide 
mortality rate from cervical cancer is 52 percent [32, 
33]. Global incidence and mortality rates depend upon 
the presence of human papillomavirus vaccination and 
screening programs for cervical cancer, which are more 
commonly available in developed countries. Developing 
countries thus carry the largest burden of cervical cancer, 
with more than eight out of ten (86%) cases diagnosed there 
in 2008 [34]. Therapy for advanced cervical cancer is still 
insufficient and presents a very important clinical problem.
In this paper, we examine the role of the MET 
receptor in the biology of cervical carcinoma. We show 
that MET receptor downregulation reduces the ability 
of tumor cells to grow in vitro and in vivo and causes 
a change in the cell phenotype to a more epithelial and 
less aggressive form, indicating the MET receptor as a 
potential therapeutic target.
Stimulation of the MET receptor via its natural 
ligand, HGF, results in scattering, angiogenesis, 
proliferation, enhanced cell motility, invasion and 
metastasis [35]. Overexpression of HGF and the MET 
receptor may also stimulate proliferation in cervical 
carcinoma cells [36]. Thus, we became interested in 
whether the MET receptor influences cell proliferation/
viability under conditions of limited oxygen and nutrients 
that resemble the environment of a growing tumor. Our 
proliferation/viability analysis revealed that MET receptor 
downregulation significantly decreased the proliferation/
viability of HTB-35 cervical carcinoma cells under 
these stress conditions. However, MET silencing did not 
noticeably alter cell proliferation/viability in two other 
cell lines. This discrepancy suggests that some cervical 
cancer patients will be more susceptible to MET blocking 
than others. Interestingly, based on our unpublished data, 
HTB-35 is the most aggressive of the three cell lines tested.
Our results further show that the constant presence 
of the MET receptor is crucial for maintaining a high 
level of proliferation in cervical cancer cells. Based on 
these findings, we became interested in whether the MET 
receptor could also influence the growth of cervical cells 
in vivo in NOD-SCID mice. We found that MET silencing 
in HTB-35 cells dramatically decreased tumor growth.
Our data thus suggest that HTB-35 cells depend 
on sustained MET activity for their growth and survival. 
This so-called “oncogene addiction” reveals a possible 
“Achilles’ heel” of cancer cells, wherein they depend 
on a single oncogenic pathway or protein for sustained 
proliferation and/or survival [37, 38]. Dependence on 
MET has been previously shown by Comoglio’s group, 
where MET could be genetically selected for the long-term 
maintenance of the primary transformed phenotype, and 
some tumors were dependent on sustained MET activity 
for their growth and survival [24, 25].
Our group has previously shown that MET 
downregulation causes a decrease in the size of tumors 
derived from rhabdomyosarcoma (RMS) cells transplanted 
into a NOD-SCID mouse model [23]. We also showed that 
MET receptor downregulation induces the differentiation 
of RMS tumors in vivo [39]. Other groups have also shown 
that MET silencing results in the impaired growth of other 
tumors, e.g., gastric and pancreatic carcinomas [40].
Here, we demonstrate for the first time that MET 
receptor downregulation inhibits cervical cancer cell 
growth in vivo in NOD-SCID mice. A histopathological 
evaluation revealed that these tumors were more 
differentiated than tumors derived from control cells. The 
MET receptor has been shown to be important for keeping 
cells of mesenchymal origin in an undifferentiated state 
(e.g., satellite cells) [41]. It is possible that during tumor 
development, some transdifferentiation takes place, which 
is more prominently revealed after MET downregulation. 
Our data suggest that the reduction in tumor size that 
occurs following MET receptor downregulation is, 
at least in part, caused by the differentiation of tumor 
cells. Our immunohistochemical analysis also revealed 
that MET receptor silencing induces the expression of 
E-cadherin in tumors formed by MET-deficient cells. 
To our knowledge, there have been no reports showing 
the re-expression of E-cadherin after MET receptor 
downregulation. E-cadherin is a transmembrane protein 
that is localized to adherens junctions along the basolateral 
surface and plays important roles in the maintenance of 
epithelial morphology and the repression of cell invasion 
and metastasis [42]. Loss of E-cadherin expression and/
or function is a well-recognized marker of EMT. Previous 
studies showed that E-cadherin expression is significantly 
decreased in cervical carcinoma tissues and almost absent 
when tumor cells invaded deeply into the parametrium or 
spread to pelvic lymph nodes [43]. Our findings provide 
evidence that MET receptor downregulation in cervical 
cancer cells can lead to reversal of the EMT phenotype 
through re-expression of E-cadherin.
Our data also provide evidence that the MET 
receptor plays an important role in regulating the growth 
and invasive behavior of cervical carcinoma cells. 
These findings suggest that MET receptor expression 
or overexpression might contribute to the resistance of 
cervical cancer to conventional methods of treatment.
Tumor growth can be regulated by increased 
proliferation, increased survival or both. We show 
that MET downregulation decreased cervical cancer 
cell proliferation. In contrast to other studies where 
MET receptor silencing promoted apoptosis [44], we 
did not observe increased apoptosis in MET-deficient 
cervical carcinoma cells. Rather, we found that MET 
downregulation altered the cell-cycle distribution such that 
shMET cells accumulated in G2/M phase. This is likely 
a consequence of the decreased expression of c-myc and 
cyclin D1 observed in shMET cells. Interestingly, these 
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results are consistent with our previous data where HGF 
upregulated cyclin D1 expression in cervical carcinoma 
cells [22].
When we examined the effect of MET 
downregulation on cell morphology and cytoskeletal 
organization, we observed a dramatic change in cell size in 
shMET HTB-35 cells. These cells were, on average, half 
the size of their control (WT and shLacZ) counterparts. 
Moreover, MET downregulation reorganized F-actin 
from thick parallel bundles into thin strands under the 
membrane. Actin filaments in epithelial cells are organized 
into thin cortical bundles, whereas they form thick 
contractile stress fibers in transdifferentiated mesenchymal 
cells [45]. This similarity suggests that MET-deficient 
HTB-35 cells have some epithelial characteristics.
To examine other mechanisms underlying the 
reduced tumor growth and change in cell morphology, we 
assessed the expression of EMT-related genes in MET-
deficient cells. We found that MET receptor downregulation 
dramatically increased E-cadherin levels and redistributed 
this protein into the localization pattern characteristic of 
epithelial cells, where it is a key component of cell–cell 
adherens junctions [46]. The level of E-cadherin correlates 
with the expression level of the SLUG transcription factor. 
We observed that MET downregulation decreased Slug 
levels in cervical cancer cells both in vitro and in vivo, 
suggesting its role in regulating E-cadherin expression in 
cervical carcinoma cells.
Our results are consistent with previous reports 
showing that SLUG plays a major role in EMT during 
breast cancer metastasis through partial inhibition of 
E-cadherin [47]. Moreover, Bolos et al. found that 
stable expression of SLUG in MDCK cells led to the 
full repression of E-cadherin and triggered a complete 
epithelial-to-mesenchymal transition [48]. Interestingly, 
restoring E-cadherin expression in lung cancer cell lines 
increased sensitivity to the cytostatic drug, gefitinib [49].
The CXCR4/CXCL12 axis can coordinate 
metastasis of a variety of cancers [30, 31]. We have 
previously found that CXCR4 expression influenced 
invasive properties of cervical carcinoma cells both in 
vitro and in vivo [50].
In this study, we have also shown for the first time 
that blocking of MET receptor can influence expression and 
function of chemokine receptors. Cells with decreased MET 
receptor expression had downregulated expression of CXCR4 
receptor. Moreover, these cells had impaired intracellular 
signaling and chemotaxis toward SDF-1 gradient, which is 
in accordance with decreased expression of CXCR4.
Until now, no published studies have evaluated the 
role of the MET receptor in promoting the EMT phenotype 
in cervical carcinoma. Our findings enable us to postulate 
that the MET receptor is a critical agent responsible for 
EMT and that blocking of MET receptor function could 
reverse this process and thus represent a new therapeutic 
strategy for advanced cervical cancer.
Our findings provide also evidence that MET 
receptor regulates growth and invasive behavior of 
cervical carcinoma cells. Thus, our data might suggest 
that MET receptor expression or overexpression could 




All cervical carcinoma cell lines used in this study: 
HeLa, HTB 34, HTB 35 were obtained from ATCC. Cells 
were maintained in MEM (Gibco BRL, Grand Island, New 
York, USA) supplemented with 10% heat-inactivated FBS 
(Gibco BRL, Grand Island, New York, USA), 100 IU/ml 
penicillin, 10 mg/ml streptomycin (Gibco BRL, Grand 
Island, New York, USA). Cells were cultured at 37oC, 5% 
CO2, 95% humidity. They were split usually twice a week 
with medium change.
Analysis of human samples
Formalin-fixed, paraffin-embedded samples from 
patients with diagnosed cervical carcinoma or dysplasia 
of the cervix were evaluated histopatologically. The 
analysis included invasive SCCs (invasive squamous 
cell carcinoma) of the cervix (n-12), HSILs (high-
grade squamous intraepithelial lesion) (n-11), LSILs 
(low-grade squamous intraepithelial lesion) (n-8) and 
normal cervix (n-9). Immunohistochemical evaluation 
was performed using primary antibodies: mouse mon-
oclonal anti E-cadherin antibody, 1:25 Clone: NCH-38; 
M3612; (DakoCytomation, Denmark), mouse monoclonal 
anti CXCR4 (Clone 44716), 1:25 (R&D System, 
Minneapolis, MN, USA), rabbit monoclonal anti Slug, 
1:25 (Cell Signaling, Danvers, Massachusetts, USA), 
rabbit polyclonal antibody anti MET, 1:50 (C-12: sc-10; 
Santa Cruz Biotech., Santa Cruz, California, USA) and 
EnVision™ Detection Systems Peroxidase/DAB, Rabbit/
Mouse (DakoCytomation, Denmark).
The samples were analysed with the approval from 
the Bioethics Committee of the Jagiellonian University 
(no. KBET/7/B/2008).
In order to perform expression analysis of the 
investigated proteins we used the following scale: 0 (+/−) – 
very poor response/poorly positive discontinuous, 1 (+) – 
poor response, 2 (++) – moderate response, 3 (+++) – quite 
strong/strong response, 4 (++++) – very strong response.
Lentiviral vectors construction, production and 
in vitro transduction
Lentiviral vectors production was performed 
as described earlier [23]. Shortly, the pENTR vector 
containing the MET- or LacZ-specific short hairpin RNA 
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(shRNA) was recombinated with pLenti6/BLOCK-iT™-
DEST expression vector (Invitrogen, Carlsbad, California, 
USA). MET shRNA sequence 5′–AGU CCG AGA UGA 
AUG UGA Att–3′ has been designed with use of available 
algorithm from Ambion http://www.ambion.com/techlib/
misc/siRNA finder.html. High titer lentiviral vector stock 
was produced in 293FT cells by transient lipofection of the 
pLenti6-GW/U6-shRNA and packaging plasmids pLP1, 
pLP2, and pLP/VSVG. Tumor cells were transduced 
directly with viral supernatants and subsequently selected 
with blasticidin (Invitrogen, Carlsbad, California, USA). 
Human cervical carcinoma cells transduced with anti MET 
shRNA were indexed with shMET, transduced with anti 
LacZ – with shLacZ label.
Analysis of cell morphology
In order to characterize the morphology of tumor 
cells, HTB-35 WT, shLacZ and shMET cells were seeded 
on cover slides and fixed with 2% of paraformaldehyde. 
Cells were photographed with Nomarski interference 
contrast optics and with epifluorescence mode. The area 
of cell surface projection, extension, elongation and 
dispersion were calculated as described by Dunn and 
Brown [51] with program MIGRA [version 1.1 RTO, 
by Ryszard Tokarski]. Extension is the measure of how 
much the shape differs from a circle. It takes a value of 
zero if the shape is circular and increases without limit as 
the shape becomes less compact [51]. Dispersion is the 
minimum extension that can be attained by compressing 
the shape uniformly. It takes a value of zero if the shape is 
circular [51]. Elongation is the measure of how much the 
shape must be compressed along its long axis to minimize 
its extension. It takes a value of zero if the shape is circular 
and increases as the shape becomes less compact [51]. 
The mean value was obtained from analysis of 50 cells. 
Statistically significant at ## p < 0.005.
Cell proliferation
Cell proliferation was measured by using the 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl] tetrazolium 
bromide (MTT) assay and cell counting. MTT assay was 
performed according to the manufacturer’s recommendat-
ions (Promega, Madison, Wisconsin, USA). Briefly, the 
cells were seeded in triplicate or sextuples in flat-bottomed 
96-well plates at 1 000 cells per well and allowed to 
adhere for 24 hours in serum supplemented (10%) media. 
Thereafter, cells were cultured under hypoxia (2% O2, 
10% FBS) and starvation (0.5% BSA) conditions. After 
24, 48, 72 and 96 hours, 20 μl of CellTiter 96 Aqueous 
One Solution reagent were added to each well and plates 
were incubated for 4 hours. Subsequently, plates were read 
at 490 nm using the ELx800 Universal Microplate Reader 
(Bio-tech) and analyzed with KC4 v3.0 with PowerReports 
software. For cell counting, cells were seeded in 24-well 
plates at 2 × 104/well. After 24, 48, 72 and 96 hours, cell 
were dissociated with 0.5% trypsin/EDTA and counted 
in a hemocytometer. Each experiment was repeated trice 
and each concentration was in triplicates. **p < 0.001 was 
considered as significant.
RNA extraction and reverse transcription
Total RNA was extracted using RNeasy Mini Kit 
(Qiagen, Valencia, California, USA) followed by DNAse 
treatment (Promega, Madison, Wisconsin, USA). The 
reverse polymerase transcription was performed using 
MMLV reverse transcriptase (Invitrogen, Carlsbad, 
California, USA) according to manufacturer’s protocol.
Quantitative real time PCR analysis
Determination of complementary DNA (cDNA) 
levels was performed by real-time polymerase chain 
reaction on an ABI PRISM 7300 Sequence Detection 
System (Applied Biosystems, Foster City, CA, USA). 
Specific primers probe sets were purchased from Applied 
Biosystems (Foster City, CA, USA). cDNA expression 
level for all samples was normalized to the housekeeping 
gene glyceraldehyde phosphate dehydrogenase (GAPDH). 
The probes sequences were as follows: Human: GAPDH 
(Hs99999905_m1), MET (Hs01565589_m1), c-myc 
(Hs00153408_m1), cyclin D1 (Hs00765553_m1), Slug 
(Hs00950344), E-cadherin (Hs01023894m1), CXCR4 
(Hs00237052_m1). 2-ΔΔCT method allowed to calculate 
relative expression of the genes.
Chemotaxis assay
The directional movement of cells toward HGF and 
SDF-1 gradient was evaluated using modified Boyden’s 
chamber with 8 μm pore polycarbonate membrane inserts 
(Transwell; Costar-Corning, Cambrige, MA, USA). 
Cells, detached with 0.25% trypsin, were seeded into the 
upper chamber of an insert at a density of 2.5 × 104 in 
100 μl, in duplicates. The lower chamber was filled with 
pre-warmed medium containing HGF (20 ng/ml) (R&D 
System, Minneapolis, MN, USA) or SDF-1 (10, 100 ng/
ml) (PeproTech EC, London, UK). 0.5% BSA DMEM 
medium was used as a negative control. After 24 hours, 
inserts were removed from the transwell and cells were 
fixed with methanol. Cells that did not migrate were 
scraped off with cotton wool from the upper membrane 
and cells that had transmigrated to the lower side of the 
membrane were stained with Wright solution and counted 
under high power field (HPF) with inverted microscope. 
At least five fields were counted each time and the mean 
number of cells per HPF was calculated. Chemotaxis 




Cells were recovered from plates with Accutase (PAA 
Laboratories, Linz, A) and stained with antibody against 
MET (monoclonal FITC-labeled anti-human HGFR/c-
MET antibody, clone 95106 (R&D System, Minneapolis, 
MN, USA) or monoclonal PE-labeled anti-human CD184 
(CXCR4) antibody, clone 12G5 (BD Pharmingen, San 
Diego, CA, USA). Briefly, 1 × 105 cells suspended in 
100 μL staining buffer (PBS, 2% FBS) were added to a test 
tube containing the appropriate amount of each antibody. 
Cells were incubated in the dark for 30 minutes at 4°C. 
Stained cells were washed and collected using a FACSCanto 
cytometer (Becton Dickinson) and analyzed with FACS 
Diva software (BD Pharmingen, San Diego, CA).
Cell cycle analysis
Cells were seeded in 100 mm dishes at a density of 
5 × 105 per dish. Twenty-four hours later, medium was 
changed and after 48 hours both adherent and floating 
cells were harvested and lysed for 10 minutes in lysing 
buffer (0.1% sodium citrate) (Sigma, St Louis, Missouri, 
USA), 0.1% Triton X-100 (Sigma, St Louis, Missouri, 
USA), 40 μg/ml Propidium Iodide (Sigma, St Louis, 
Missouri, USA). Cells were analyzed for DNA content 
by flow cytometry with FACSCanto Cytofluorometer (BD 
Pharmingen, San Diego, CA) and the cell-cycle phases 
were analyzed using FCS Express V3 with MultiCycle AV 
(http://www.denovosoftware.com).The experiments were 
performed twice with similar results.
Apoptosis assay by flow cytometry
Apoptosis was measured by flow cytometry using an 
Annexin V-FITC Apoptosis Detection kit I (BD Pharmingen, 
San Diego, CA). Briefly, cells were cultured in MEM 
supplemented with 10% FBS, 1 × 106 cells were washed with 
cold PBS and then resuspended in 1 × cold binding buffer 
plus 5 μl Annexin V-FITC and 5 μl PI (propidium iodide). 
After 15 min incubation at RT in the dark, samples were 
analyzed by dual color flow cytometry on a FACSCanto 
Cytofluorometer (BD Pharmingen, San Diego, CA).
Western blot
Western blots were done on extracts prepared from 
cells as described previously [39, 50]. Briefly, CC cells 
were lysed (for 10 min) on ice in M-Per lysing buffer 
(Pierce, Rockford, Illinois, USA) containing protease 
and phosphatase inhibitors (Sigma, St Louis, Missouri, 
USA). Subsequently, the extracted proteins were separated 
on a 12% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) gel, and fractionated proteins 
were transferred into a PVDF membrane (BioRad; BioRad 
Laboratories, Hecules, CA, USA). Total level of c-myc 
was detected by primary rabbit polyclonal antibody (Cell 
Signaling, Danvers, Massachusetts, USA). Total level of 
cyclin D1 and Slug was assessed using rabbit monoclonal 
antibodies (Cell Signaling, Danvers, Massachusetts, 
USA). The level of Slug was detected using rabbit 
monoclonal anti-Slug antibody, (Cell Signaling, Danvers, 
Massachusetts, USA). The phosphorylation of AKT and 
MAPK was assessed using primary rabbit anti-phospho-
AKT (Ser 473) and mouse anti-phospho-MAPK (Thr202/
Tyr204) antibodies both from Cell Signaling Danvers, 
Massachusetts, USA. They were subsequently detected with 
horseradish peroxidase (HRP)-conjugated goat anti-rabbit or 
anti-mouse secondary antibody (Santa Cruz Biotech., Santa 
Cruz, California, USA). The membranes were developed 
with an enhanced chemiluminescence (ECL) reagent 
(Amersham Life Sciences, Little Chalfont, UK), dried, and 
subsequently exposed to the HyperFilm (Amersham Life 
Sciences, Little Chalfont, UK). An equal loading in the 
lanes was evaluated by probing with rabbit anti-GAPDH 
from Cell Signaling, Danvers, Massachusetts, USA.
Fluorescence microscopy studies
For fluorescence microscopy studies, cells were 
plated on glass coverslips. 48 hours after seeding cells 
were fixed with 4% paraformaldehyde in PBS for 30 min 
at room temperature (RT). For F-actin staining, cells were 
incubated with Alexa 488–conjugated phalloidin (Sigma, 
St Louis, Missouri, USA), (1:500) diluted in 0.1% BSA for 
1 h. To detect E-cadherin cells were permeabilized in PBS 
containing 1% triton X-100 for 20 min, blocked with 1% 
BSA in PBS for 30 min and then incubated with primary 
anti-E-cadherin antibody (BD Pharmingen, San Diego, CA, 
USA) (1:50) diluted in 1% BSA, overnight at 4°C. After 
several washes with PBS, the samples were incubated with 
Alexa Fluor 488-conjugated anti-mouse secondary antibody 
(1:1000) (Invitrogen, Carlsbad, California, USA) for 1 h 
at RT and embedded in Vectahield (Vector Laboratories, 
Burlingame, CA, USA). Cells were visualized in an 
Olympus BX-51 microscope with the appropriate filters. 
Representative images were taken with a Spot 4.3 digital 
camera and software and edited in Adobe Photoshop.
Long-term murine models
For long term-assay 5 × 106 CC cells were injected 
subcutaneously into 6–8 weeks NOD-SCID mice. 
After 30 days mice were killed and their tumors were 
harvested. Tumors were weighted and fixed in formalin. 
Immunohistochemical evaluation was performed using 
anti-E-cadherin monoclonal primary antibody (Clone: 
NCH-38; M3612; DakoCytomation, Denmark) and anti-
Slug rabbit monoclonal antibody (Cell Signaling, Danvers, 
Massachusetts, USA) and LSAB+ Kit (DakoCytomation, 
Carpinteria, CA, USA). Each experimental group 
comprised of 5 animals and experiments were repeated 
at least three times. **p < 0.001 was considered as 
significant. All experimental procedures were carried out 
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according to the Jagiellonian University guidelines for the 
use and care of laboratory animals and were approved by I 
Local Ethics Committee in Krakow (no. 55/2011).
Statistical analysis
Statistical analysis, unless otherwise indicated, 
was performed using the two-tailed Student’s t-test. 
All experiments were performed at least three times 
(chemotaxis analysis and real-time RT-PCR additionally 
in duplicates). p values, lower than 0.01 (*), 0.001 (**), 
0.05 (#), 0.005 (##), were considered as significant.
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